Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell Carcinoma: a prospective evaluation

Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell Carcinoma: a prospective evaluation

<p>Abstract</p> <p>Background</p> <p>Sarcomatoid renal cell cancer (RCC) is a distinct histological variant of RCC that is associated with rapid progression and a poor prognosis. The optimal treatment for patients with sarcomatoid RCC remains to be defined. Gemcitabine...

Full description

Bibliographic Details
Main Authors: Staehler M, Haseke N, Roosen A, Stadler T, Bader M, Siebels M, Karl A, Stief CG
Format: Article
Language:English
Published: BMC 2010-07-01
Series:European Journal of Medical Research
Subjects:
renal cell carcinoma
sarcomatoid
chemotherapy
sorafenib
multi-kinase inhibitor
survival
angiogenesis
Online Access:http://www.eurjmedres.com/content/15/7/287

Internet

http://www.eurjmedres.com/content/15/7/287

Similar Items